NVIDIA and Lilly Launch AI-Driven Lab to Accelerate Drug Discovery
NVIDIA and Eli Lilly unveiled a first-of-its-kind AI co-innovation lab in the San Francisco Bay Area, committing up to $1 billion over five years to fuse Lilly’s biology and medicine expertise with NVIDIA’s AI and accelerated computing, via the BioNeMo platform and Vera Rubin architecture. The initiative will create a continuous learning system that links Lilly’s wet labs with computational dry labs for 24/7 AI-assisted experimentation, develop large biomedical foundation and frontier models, and extend into manufacturing, clinical development, and supply chains using robotics, digital twins, and physical AI. The lab is set to begin in South San Francisco this year, aiming to accelerate drug discovery and scale medicine production through enhanced AI infrastructure and collaboration between the two companies’ experts and ecosystems.
